Rapid Effects of the DPP-4 Inhibitor Linagliptin on Monocyte Polarization in Type 2 Diabetic Patients With and Without Chronic Renal Failure. A Randomized Cross-over Trial Versus Placebo
Phase of Trial: Phase IV
Latest Information Update: 18 Sep 2015
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 06 Sep 2012 Planned end date changed from 1 May 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.